Cornerstone BioPharma, Inc. (www.cornerstonebiopharma.com), located next to North Carolina’s Research Triangle Park, is an emerging specialty pharmaceutical company that is currently focused on the development and commercialization of niche prescription medications in the respiratory arena. Cornerstone is actively engaged in strategic licensing of additional prescription products through acquisitions, strategic partnerships and new product development.
Cornerstone BioPharma™, the Triangle-based specialty pharmaceutical company currently focused on the development and commercialization of niche prescription medications in the respiratory arena, today announced it has signed a co-promotion agreement with SJ Pharmaceuticals (SJP).
Cornerstone BioPharma (“Cornerstone”) of Cary, North Carolina, and J-Med Pharmaceuticals (“J-Med”) of Boston, Massachusetts, today announced that they have settled pending patent litigation with Sovereign Pharmaceuticals, Ltd., (“Sovereign”) of Fort Worth, Texas, in connection with U.S. Patent No. 6,270,796 (“the ‘796 patent”). The litigation was brought by the patent owner J-Med and licensee Cornerstone, who markets and sells the AlleRx™ Dose Pack.
Cornerstone BioPharma™, the Triangle-based specialty pharmaceutical company currently focused on the development and commercialization of niche prescription medications in the respiratory arena, today announced the company has obtained exclusive U.S. licensing rights from leading Japanese pharmaceutical company Meiji Seika Kaisha for Spectracef (cefditoren pivoxil).
